RxDoctor Payments Data

Andrew Gorman, DO

Neurology · Sun City, AZNPI 1265403513

Payments from drug & device makers

$15,437in general payments, 2019–2025

Across 1,121 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • UCB, Inc.$2K
  • AbbVie$1K
  • Acadia Pharmaceuticals Inc$1K
  • Novartis$761
  • Amneal Pharmaceuticals LLC$613
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,13098%
  • Education$3072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.122$1,544
UCB, Inc.142$1,534
AbbVie(2 entities)104$1,285
Acadia Pharmaceuticals Inc105$1,160
Novartis80$761
Amneal Pharmaceuticals LLC47$613
Biogen43$583
Argenx US, Inc.44$581
SK Life Science, Inc.25$526
MDD US Operations, LLC24$509
AstraZeneca26$495
Eisai Inc.23$463
Genentech USA, Inc.20$405
Bristol Myers Squibb30$381
EMD Serono, Inc.24$347
Abbott13$291
Amgen(2 entities)20$288
Banner Life Sciences, LLC38$278
Avion Pharmaceuticals16$249
Neuropace, Inc.16$246
Lundbeck LLC16$202
Grifols USA, LLC8$188
TG Therapeutics, Inc.8$177
Jazz Pharmaceuticals Inc.6$144
Boston Scientific3$128
Lilly USA, LLC8$127
Pfizer7$127
Sunovion Pharmaceuticals Inc.9$110
Sanofi5$109
Aucta Pharmaceuticals, Inc.10$103
Catalyst Pharmaceuticals, Inc.6$90
C2n Diagnostics, LLC4$89
Otsuka America Pharmaceutical, Inc.5$87
Neurocrine Biosciences, Inc.5$87
Sumitomo Pharma America, Inc.4$65
W. L. Gore & Associates, Inc.1$65
Supernus Pharmaceuticals, Inc.4$63
GE HealthCare4$61
Impel Pharmaceuticals Inc.4$60
Takeda Pharmaceuticals U.S.A., Inc.2$59
Vertiflex, Inc.3$59
Kyowa Kirin, Inc.3$55
Biohaven Pharmaceuticals, Inc.3$48
Stryker1$45
Johnson & Johnson2$43
Avanir Pharmaceuticals, Inc.2$36
Vanda Pharmaceuticals Inc.2$35
Tanabe Pharma America, Inc.2$33
E.r. Squibb & Sons, L.L.C.1$32
Merz Pharmaceuticals, LLC1$30
Scilex Pharmaceuticals Inc.2$29
Insightec,inc1$29
Medtronic1$28
Cycle Pharmaceuticals Inc2$27
Xeris Pharmaceuticals, Inc.1$22
Bio Products Laboratory USA, Inc.1$20
Akcea Therapeutics, Inc.1$20
Cala Health, Inc.1$19
Globus Medical1$18
Strongbridge US Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,437 in reported general payments places this provider in the 65th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$597,758
Medicare patients
1,451
Services billed
4,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab14$156,367
NuplazidPimavanserin Tartrate26$128,143
AustedoDeutetrabenazine14$81,579
NayzilamMidazolam27$71,564
BriviactBrivaracetam42$61,807
Emgality PenGalcanezumab-Gnlm82$61,384
Ajovy AutoinjectorFremanezumab-Vfrm60$56,119
UbrelvyUbrogepant36$44,211
Nurtec OdtRimegepant Sulfate19$43,083
EpidiolexCannabidiol (Cbd)14$31,318
Aimovig AutoinjectorErenumab-Aooe26$25,265
Lacosamide166$18,987
FycompaPerampanel14$16,932
Memantine Hcl501$14,991
Gabapentin651$13,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Nayzilam, Briviact$1,534$133,37169 claims
Acadia Pharmaceuticals IncNuplazid$1,160$128,14326 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,544$81,57914 claims
AbbVieUbrelvy$1,285$44,21136 claims
PfizerNurtec Odt$127$43,08319 claims
Eisai Inc.Fycompa$463$16,93214 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$613$15,730146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 neurology providers in Arizona.

Other neurology in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →